{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:00:56Z","timestamp":1740135656175,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18H02883","JP23390329"],"award-info":[{"award-number":["JP18H02883","JP23390329"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1245\/s10434-018-07145-2","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T17:22:14Z","timestamp":1547659334000},"page":"1093-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14"],"prefix":"10.1245","volume":"26","author":[{"given":"Tomohisa","family":"Okuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Togano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Wanibuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaichi","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"issue":"2","key":"7145_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"7145_CR2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/bjc.1996.496","volume":"74","author":"M Yashiro","year":"1996","unstructured":"Yashiro M, Chung YS, Kubo T, Hato F, Sowa M. Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer. 1996;74(7):1096\u2013103.","journal-title":"British journal of cancer."},{"issue":"3","key":"7145_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.amjsurg.2004.06.010","volume":"188","author":"E Otsuji","year":"2004","unstructured":"Otsuji E, Kuriu Y, Okamoto K, et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg. 2004;188(3):327\u201332.","journal-title":"American journal of surgery."},{"issue":"1","key":"7145_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1\u201327.","journal-title":"Gastric Cancer."},{"key":"7145_CR5","doi-asserted-by":"publisher","unstructured":"Yashiro M, Matsuoka T, Ohira M. The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models. Hum Cell. Epub 6 Jun 2018. https:\/\/doi.org\/10.1007\/s13577-018-0211-4 .","DOI":"10.1007\/s13577-018-0211-4"},{"issue":"1","key":"7145_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10120-014-0444-1","volume":"19","author":"P Grygielewicz","year":"2016","unstructured":"Grygielewicz P, Dymek B, Bujak A, et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer. 2016;19(1):53\u201362.","journal-title":"Gastric cancer."},{"issue":"4","key":"7145_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/bjc.2011.603","volume":"106","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106(4):727\u201332.","journal-title":"British journal of cancer."},{"issue":"11","key":"7145_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/bjc.2017.330","volume":"117","author":"KP Papadopoulos","year":"2017","unstructured":"Papadopoulos KP, El-Rayes BF, Tolcher AW, et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017;117(11):1592\u20139.","journal-title":"British journal of cancer."},{"issue":"1","key":"7145_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2217\/fon.14.208","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Giglione P, Liguigli W, Paglino C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Fut Oncol. 2015;11(1):39\u201350.","journal-title":"Future Oncol."},{"issue":"5","key":"7145_CR10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","volume":"19","author":"E Angevin","year":"2013","unstructured":"Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19(5):1257\u201368.","journal-title":"Clinical cancer research."},{"issue":"6","key":"7145_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","volume":"28","author":"E Cutsem Van","year":"2017","unstructured":"Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316\u201324.","journal-title":"Annals of oncology."},{"issue":"3","key":"7145_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276\u201382.","journal-title":"Journal of clinical oncology."},{"issue":"30","key":"7145_CR13","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33(30):3401\u20138.","journal-title":"Journal of clinical oncology."},{"issue":"4","key":"7145_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","volume":"12","author":"M Michael","year":"2017","unstructured":"Michael M, Bang YJ, Park YS, et al. A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer. Target Oncol. 2017;12(4):463\u201374.","journal-title":"Patients with Advanced Cancer. Targeted oncology."},{"issue":"7","key":"7145_CR15","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855\u201362.","journal-title":"Clinical cancer research."},{"issue":"7","key":"7145_CR16","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-07-5229","volume":"68","author":"K Kunii","year":"2008","unstructured":"Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68(7):2340\u20138.","journal-title":"Cancer research."},{"issue":"5","key":"7145_CR17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1053\/j.gastro.2006.08.030","volume":"131","author":"K Nakamura","year":"2006","unstructured":"Nakamura K, Yashiro M, Matsuoka T, et al. A novel molecular targeting compound as K-samII\/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology. 2006;131(5):1530\u201341.","journal-title":"Gastroenterology."},{"issue":"15","key":"7145_CR18","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1073\/pnas.87.15.5983","volume":"87","author":"Y Hattori","year":"1990","unstructured":"Hattori Y, Odagiri H, Nakatani H, et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc. Natl. Acad. Sci. USA. 1990;87(15):5983\u20137.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"4","key":"7145_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5946\/ce.2016.057","volume":"49","author":"K Jung","year":"2016","unstructured":"Jung K, Park MI, Kim SE, Park SJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc. 2016;49(4):336\u201345.","journal-title":"Clin Endosc."},{"issue":"7731","key":"7145_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(71)90287-X","volume":"2","author":"M Seabright","year":"1971","unstructured":"Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971;2(7731):971\u20132.","journal-title":"Lancet."},{"issue":"11","key":"7145_CR21","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.27931","volume":"132","author":"A Capes-Davis","year":"2013","unstructured":"Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int. J. Cancer. 2013;132(11):2510\u20139.","journal-title":"International journal of cancer."},{"issue":"4","key":"7145_CR22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ijc.24763","volume":"126","author":"M Yashiro","year":"2010","unstructured":"Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int. J. Cancer. 2010;126(4):1004\u201316.","journal-title":"International journal of cancer."},{"issue":"9","key":"7145_CR23","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","volume":"19","author":"L Xie","year":"2013","unstructured":"Xie L, Su X, Zhang L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013;19(9):2572\u201383.","journal-title":"Clinical cancer research."},{"issue":"4","key":"7145_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","volume":"35","author":"H Saka","year":"2017","unstructured":"Saka H, Kitagawa C, Kogure Y, et al. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Investig New Drugs. 2017;35(4):451\u201362.","journal-title":"Investigational new drugs."},{"issue":"20","key":"7145_CR25","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/jm2006222","volume":"54","author":"V Guagnano","year":"2011","unstructured":"Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011;54(20):7066\u201383.","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"7145_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2","volume":"83","author":"RA MacLeod","year":"1999","unstructured":"MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer. 1999;83(4):555\u201363.","journal-title":"International journal of cancer."},{"issue":"24","key":"7145_CR27","first-page":"8848","volume":"63","author":"K Nakazawa","year":"2003","unstructured":"Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003;63(24):8848\u201352.","journal-title":"Cancer Res."},{"issue":"5","key":"7145_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/bjc.2014.61","volume":"110","author":"YJ Liu","year":"2014","unstructured":"Liu YJ, Shen D, Yin X, et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer. 2014;110(5):1169\u201378.","journal-title":"British journal of cancer."},{"issue":"4","key":"7145_CR29","first-page":"875","volume":"21","author":"T Toyokawa","year":"2009","unstructured":"Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep. 2009;21(4):875\u201380.","journal-title":"Oncology reports."},{"issue":"8","key":"7145_CR30","first-page":"1373","volume":"2","author":"Y Hattori","year":"1996","unstructured":"Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996;2(8):1373\u201381.","journal-title":"Clinical cancer research."},{"issue":"1","key":"7145_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12307-010-0036-5","volume":"3","author":"M Yashiro","year":"2010","unstructured":"Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 2010;3(1):127\u201335.","journal-title":"Cancer Microenviron."},{"issue":"2","key":"7145_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280\u2013300.","journal-title":"Medicinal research reviews."},{"issue":"8","key":"7145_CR33","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045\u201356.","journal-title":"Cancer research."},{"issue":"13","key":"7145_CR34","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1245\/s10434-011-1768-2","volume":"18","author":"S Noda","year":"2011","unstructured":"Noda S, Yashiro M, Toyokawa T, et al. Borrmann\u2019s macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis. Ann Surg Oncol. 2011;18(13):3718\u201325.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"7145_CR35","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1007\/s00464-018-6138-8","volume":"32","author":"Y Oono","year":"2018","unstructured":"Oono Y, Kuwata T, Takashima K, et al. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surg Endosc. 2018;32(9):3964\u201371.","journal-title":"Surgical endoscopy."},{"issue":"4","key":"7145_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3892\/etm_00000086","volume":"1","author":"Y Fuyuhiro","year":"2010","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med. 2010;1(4):547\u201351.","journal-title":"Exp Ther Med."},{"issue":"11","key":"7145_CR37","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.ajpath.2016.07.024","volume":"186","author":"H Kasashima","year":"2016","unstructured":"Kasashima H, Yashiro M, Nakamae H, et al. CXCL1-chemokine (C-X-C Motif) receptor 2 signaling stimulates the recruitment of bone marrow-derived mesenchymal cells into diffuse-type gastric cancer stroma. Am J Pathol. 2016;186(11):3028\u201339.","journal-title":"Am J Pathol."},{"issue":"7","key":"7145_CR38","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/bjc.2011.330","volume":"105","author":"Y Fuyuhiro","year":"2011","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Upregulation of cancer-associated myofibroblasts by TGF-beta from scirrhous gastric carcinoma cells. Br J Cancer. 2011;105(7):996\u20131001.","journal-title":"Br J Cancer."},{"issue":"4","key":"7145_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1349-7006.2012.02209.x","volume":"103","author":"Y Fuyuhiro","year":"2012","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Cancer-associated orthotopic myofibroblasts stimulates the motility of gastric carcinoma cells. Cancer Sci. 2012;103(4):797\u2013805.","journal-title":"Cancer Sci."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-07145-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-07145-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-07145-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:18:23Z","timestamp":1720930703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-07145-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["7145"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-07145-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no financial or other interests with regard to the submitted manuscript that might be construed as a conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}